Day 2: June 19, 2026 
Advancing the Vision: Leveraging Clinical Evidence and the Patient Voice

9:30 a.m. – 9:40 a.m.

Conference Day 2 Opening

A brief recap of sessions from day one:
 

9:40 a.m. – 10:00 a.m.

Welcome to Day 2 from CCRAN’s President & CEO

A warm welcome and sincere thanks to all experts and participants. Key highlights in this session: 
‍

10:00 a.m. – 11:30 a.m.

A National Conversation on CGP Becoming a Standard of Care (Clinician Roundtable)

As provinces across Canada work to advance access to comprehensive genomic profiling (CGP), clinical teams are navigating varying system conditions, infrastructure, and expectations. This national roundtable will bring together frontline clinicians to build clinical consensus that CGP should be established as a standard of care, and to identify the conditions needed to support equitable, informed clinical decision-making across Canada.

Panelists will reflect on their jurisdictional contexts, identifying shared challenges and enablers related to team capacity, informatics, turnaround times, and lab resources. Rather than prescribing a uniform approach, the session will focus on identifying where alignment is most needed, across care settings, provinces, and specialties, to advance CGP in a way that is both scalable and responsive to local needs.

Key objectives:
‍

11:30 a.m. – 12:15 p.m.

Health Break

12:15 p.m. - 1:30 p.m.  

Unlocking the Research Pipeline: Bridging Clinical Trials and Real-World Genomics

As comprehensive genomic profiling (CGP) moves toward standard of care, the ability to translate genomic data into actionable evidence becomes increasingly critical. This session examines how real-world CGP data and coordinated genomic infrastructure can strengthen Canada’s research ecosystem, particularly where traditional trial evidence is limited. By focusing on data integration, evidence generation, and national coordination, the discussion will consider how genomics can better inform research, regulatory, and system-level decision-making, and support a more connected, pan-Canadian approach to precision oncology innovation.  

This session will explore:
‍

1:30 p.m. – 2:45 p.m.

Patient Group Reflections on the Case for Biomarker Investment (Patient Group Roundtable)

As health systems across Canada consider the broader integration of biomarker testing into standard cancer care, patient groups play a critical role in highlighting access gaps and articulating priorities for investment. This roundtable brings together patient organizations from across tumour types to reflect on their experiences advocating for biomarker testing within diverse health system contexts. The discussion will focus on how patient groups identify unmet needs, coordinate advocacy efforts, and define what meaningful biomarker investment looks like from a patient and community perspective.  

Speakers will elaborate on the following topics:

2:45 p.m. – 3:00 p.m.

Health Break

3:00 p.m. – 4:00 p.m.

Scaling What Matters: Building on Economic Analysis to Help Inform Policy

As Canada progresses toward a more aligned approach to comprehensive genomic profiling (CGP) in metastatic cancer care, economic analysis is emerging as a central lever for advancing shared understanding across clinical, policy, and patient communities. This session will explore how the cost and benefit findings can clarify the value of CGP from multiple vantage points and support a more coordinated national dialogue. Panelists will reflect on how economic insights can be translated into strategic, scalable insights to inform future system planning. The discussion will emphasize where stakeholder priorities converge and how economic considerations can be used to inform coordinated CGP planning across provinces.

Guiding objectives include:
‍

4:00 p.m. – 5:00 p.m.  

From Laboratory Readiness to Patient Impact: Why CGP Falls Short and What Must Change

As comprehensive genomic profiling (CGP) demonstrates clear clinical and economic value, persistent implementation barriers continue to limit its consistent funding and delivery across Canada. This session examines the most pressing constraints preventing CGP from becoming routine practice, with a particular focus on laboratory capacity, diagnostic workflows, and system readiness conditions.

The discussion connects system-level barriers, such as variable testing criteria, turnaround times, and fragmented processes, to their downstream impact on patient care. By examining system and policy considerations through a real-world patient lens, the session aims to clarify where breakdowns occur and what is required to move CGP from inconsistent access to sustained, reliable integration within routine cancer care.

This multi-disciplinary panel will explore:
‍

5:00 p.m. – 5:15 p.m.

Day 2 Closing Remarks and Conference Adjournment.